Endocrine Disruptor Screening Program Research Articles

Good Laboratory Practices: Myers et al. Respond

Good Laboratory Practices: Myers et al. Respond

Screening of Potentially Hormonally Active Chemicals Using Bioluminescent Yeast Bioreporters

Saccharomyces cerevisiae bioluminescent bioreporter assays were developed previously to assess a chemical's estrogenic or androgenic disrupting potential. S. cerevisiae BLYES, S. cerevisiae BLYAS, S. cerevisiae BLYR, were used to assess their reproducibility and utility in screening 68, 69, and 71 chemicals for estrogenic, androgenic, and toxic effects, respectively. EC(50) values were 6.3 +/- 2.4 x 10(-10)M (n = 18) and 1.1 +/- 0.5 x 10(-8)M (n = 13) for BLYES and BLYAS, using 17beta-estradiol and 5alpha-dihydrotestosterone over concentration ranges of 2.5 x 10(-12) through 1.0 x 10(-6)M, respectively. Based on analysis of replicate standard curves and comparison to background controls, a set of quantitative rules have been formulated to interpret data and determine if a chemical is potentially hormonally active, toxic, both, or neither. The results demonstrated that these assays are applicable for Tier I chemical screening in Environmental Protection Agency's Endocrine Disruptor Screening and Testing Program as well as for monitoring endocrine-disrupting activity of unknown chemicals in water.

TESTS OF ENDOCRINE DISRUPTORS DELAYED

IT HAS BEEN 12 YEARS since Congress ordered the Environmental Protection Agency to develop the Endocrine Disruptor Screening Program (EDSP) to test pesticides and other chemicals for their ability to mimic hormones and disrupt the endocrine system. After missing numerous deadlines and spending more than $100 million on the program, EPA has yet to test a single chemical. Many people are wondering whether EDSP will ever get off the ground, and critics are saying it’s time to scrap the program and start over. Frustrated by EPA’s foot-dragging, Congress added language to EPA’s 2008 appropriations bill that directed the agency to finalize the initial list of chemicals and assays to be used in EDSP and issue the first test orders by the end of August of this year. To date, however, EPA has only issued a draft list of 73 pesticides or inert ingredients used in making pesticides that will undergo screening and a draft list ...

High throughput adjustable 96-well plate assay for androgen receptor binding: A practical approach for EDC screening using the chimpanzee AR

The issue as to whether natural and man-made chemicals interfere with endocrine function has raised concerns. This interference could be biologically significant even at very low doses if the chemicals interact deleteriously with hormone receptors at low concentrations. Therefore, the United States Environmental Protection Agency (USEPA) Office of Coordination and Policy (OSCP) requested that a nonhuman mammalian androgen receptor binding assay be developed for possible use in their Endocrine Disruptor Screening Program (EDSP). Ideally, this assay would be high throughput, not use animals as a source of receptor protein, easily deployed throughout the scientific community, utilize reagents available to both the public and private sector, and have the potential for future automation. We developed a highly modified 96-well plate assay which meets these criteria. It employs a baculovirus expressed recombinant primate androgen receptor which is publically available and exploits the unique ability of some mammalian androgen receptors to remain biologically active after guanidine hydrochloride (GdnHCl) solubilization. This GdnHCl treated receptor remains soluble and requires no additional purification prior to use. We provide a very detailed description of the assay protocol itself, and similarly detailed method for producing and solublizing the receptor.

Building the endocrine disruptor screening program: EPA makes progress

Environmental Quality ManagementVolume 17, Issue 2 p. 71-80 Columns Building the endocrine disruptor screening program: EPA makes progress Lynn L. Bergeson, Lynn L. Bergeson Bergeson & Campbell, P.C., Washington, D.C.Search for more papers by this author Lynn L. Bergeson, Lynn L. Bergeson Bergeson & Campbell, P.C., Washington, D.C.Search for more papers by this author First published: 17 December 2007 https://doi.org/10.1002/tqem.20167AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume17, Issue2Winter 2007Pages 71-80 RelatedInformation

Dietary Dose: Rodent Feed Affects ED Screening Results

As the U.S. EPA begins its program to test endocrine-disrupting effects of pesticides, researchers caution that routine screening methods could distort results [EHP 115:1717–1726; Thigpen et al.]. The team discovered that some commercially available rodent diets can cause early sexual maturation similar to that induced by chemical endocrine disruptors. Furthermore, one rat strain commonly used by many researchers is not the most sensitive to the effects of endocrine disruptors and thus may not provide optimal results. The U.S. EPA Endocrine Disruptor Screening Program was mandated by Congress in 1996 amid mounting evidence that hormone-mimicking chemicals in the environment alter sexual traits in exposed wildlife. Research suggests these chemicals might also contribute to increases in human male reproductive disorders including poor sperm quality, cryptorchidism, and hypospadias. In June 2007 the U.S. EPA published a list of 73 suspect chemicals for initial screening. According to the authors of the current study, some rodent diets could distort screening results because they contain high levels of plant estrogens. The phytoestrogens genistein and daidzein are found in the soybeans used in many rodent diets. U.S. EPA guidelines allow a limited amount of genistein and daidzein in the diets of rodents used for screening. The authors report, however, that even approved levels of these compounds are sufficient to adversely impact sexual end points that researchers use to measure endocrine disruption. Furthermore, genistein and daidzein levels vary significantly among different batches of the same diet. Rats on a diet with the highest genistein and daidzein concentrations reached sexual maturity several days earlier than those fed a different batch of the same diet containing lower levels of the compounds. In addition, rodents on high-calorie diets grew faster and reached sexual maturity earlier than those fed a low-calorie diet. The researchers measured sexual maturity by observing the day each rodent’s vagina opened. Vaginal opening provides a non-invasive measurement that does not require the animal to be sacrificed. In contrast, sexual maturity is typically measured by uterine weight, which increases at puberty. The results revealed that dietary estrogens had a lesser effect on the vaginal opening day of Sprague-Dawley rats than on Fischer 344 rats or CD-1 mice. This indicates that the latter two species may be more sensitive to exogenous estrogens and thus are preferable for screening. The authors call on scientists screening suspected endocrine disruptors to choose the most sensitive rodents, to minimize the animals’ exposure to dietary estrogens, and to control their caloric intake. Only then, they write, will scientists obtain results that are the most accurate, reproducible, and easiest to compare among laboratories.

Substitution of synthetic chimpanzee androgen receptor for human androgen receptor in competitive binding and transcriptional activation assays for EDC screening

The potential effect of receptor-mediated endocrine modulators across species is of increasing concern. In attempts to address these concerns, we are developing androgen and estrogen receptor binding assays using recombinant hormone receptors from a number of species across different vertebrate classes. The United States Environmental Protection Agency (USEPA) Office of Science Coordination and Policy (OSCP) requested that we develop a nonhuman mammalian receptor-binding assay for possible use in their Endocrine Disruptor Screening Program (EDSP). Since the chimpanzee androgen receptor is very similar to that of humans and thus possesses properties which could be exploited in future endocrine studies, we synthesized and expressed this gene in eukaryotic expression plasmids, baculovirus expression vectors and replication deficient adenovirus. In all ligand-binding and transcriptional activation assays tested, the chimpanzee receptor performed essentially identically to the human receptor. This suggests that the chimpanzee gene could substitute for the human gene in endocrine screening assays.

Evaluation of ammonium perchlorate in the endocrine disruptor screening and testing program's male pubertal protocol: Ability to detect effects on thyroid endpoints

The U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male pubertal protocol was designed as a screen to detect endocrine-disrupting chemicals which may alter reproductive development or thyroid function. One purpose of this in vivo screening protocol is to detect thyrotoxicants via a number of different mechanisms of action, such as thyroid hormone synthesis or clearance. Here we evaluate the ability of this EDSP male pubertal protocol to detect the known thyrotoxicant ammonium perchlorate as an endocrine disruptor. Ammonium perchlorate is a primary ingredient in rocket fuel, fertilizers, paints, and lubricants. Over the past 50 years, potassium perchlorate has been used to treat hyperthyroidism in humans. Perchlorate alters thyroid hormone secretion by competitively inhibiting iodide uptake by the thyroid gland. In this study, ammonium perchlorate was administered at 62.5, 125, 250, and 500 mg/kg to male Wistar rats based on a pilot study of oral dosing. Doses of 125–500 mg/kg perchlorate decreased T4 in a dose-dependent manner. TSH was significantly increased in a dose-responsive manner at the same doses, while T3 was unchanged at any dose. Thyroid histology was significantly altered at all doses, even at the 62.5 mg/kg, with a clear dose-dependent decrease in colloid area and increase in follicular cell height. No effects on preputial separation, a marker of pubertal progression, or reproductive tract development were observed at any dose. These results demonstrate that the male pubertal protocol is useful for detecting thyrotoxicants which target the thyroid axis by this mechanism (altered uptake of iodide). This study also found that perchlorate exposure during this period did not alter any of the reproductive developmental endpoints.

Nature of the Binding Interaction for 50 Structurally Diverse Chemicals with Rat Estrogen Receptors

This study was conducted to characterize the estrogen receptor (ER)-binding affinities of 50 chemicals selected from among the high production volume chemicals under the U.S. EPA's (U.S. Environmental Protection Agency's) Toxic Substances Control Act inventory. The chemicals were evaluated using the rat uterine cytosolic (RUC) ER-competitive binding assay, with secondary analysis using Lineweaver-Burk plots and slope replots to confirm true competitive inhibition and to determine an experimental K(i). Data from these ER-competitive binding assays represent the types of competitive binding curves that can be obtained when screening chemicals with broad structural diversity. True competitive inhibition was observed in 17 of 50 chemicals. Binding affinities were much lower than that of estradiol (E(2)) with K(i) concentrations ranging from 0.6 to 373 microM as compared with that of E(2) (0.77 nM). Other chemicals that appeared to displace radiolabeled E(2) binding to ER were, in fact, found not to be competitive inhibitors in the secondary K(i) experiments. These seven chemicals likely altered the stability of the assay by changing the buffer pH, denaturing ER, or disrupting the ER-binding kinetics. Thus, several conditions that may confound interpretation of RUC ER-binding assay data are illustrated. For another group of eight chemicals, neither an IC(50) nor K(i) could be determined due to solubility constraints. These chemicals exhibited slight (20-40%) inhibition at concentrations of 10-100 microM, suggesting that they could be competitors at very high concentrations, yet K(i) experiments were not possible as the limit of chemical solubility in the aqueous assay buffer was well above the IC(50). An additional 18 of the 50 chemicals were classified as nonbinders because in concentrations up to 100 microM they produced essentially no displacement of radiolabeled E(2). These results show that although the ER-competitive binding assay is a valuable tool for screening chemicals, secondary tests such as a double reciprocal Lineweaver-Burk experiment with slope replot should be used to confirm true competitive inhibition. This information will be useful for the ongoing validation of the RUC ER-competitive binding assay under the U.S. EPA's Endocrine Disruptor Screening Program, as well as to support research efforts to develop computational models designed to identify chemicals with the ability to bind to ER.

Marsupial development in the mysid Neomysis integer (Crustacea: Mysidacea) to evaluate the effects of endocrine-disrupting chemicals

Embryonic development is a crucial time window within an organism's life history. Relatively few studies have focused on understanding the potential effects of endocrine disruptors on embryogenesis in invertebrates. Mysids (Crustacea: Mysidacea) have been used extensively in regulatory toxicity testing and they are the only invertebrate model currently included in the U.S. EPA's Endocrine Disruptor Screening and Testing Program. We developed a method for studying mysid embryonic development in multiwell plates until the release of free-swimming juveniles. This method was used to evaluate the potential effects of the insecticide methoprene, a juvenile hormone analog, on mysid embryogenesis. Embryos were exposed to nominal concentrations 0.01, 1, and 100 μg methoprene/L. Average percentage survival, hatching success, total development time and duration of each developmental stage were analyzed. Embryos exposed to 1 and 100 μg methoprene/L had a significantly lower hatching success and lower survival rates. Our study indicates that in vitro embryogenesis can be used as a valuable tool to study the impact of endocrine disruptors in mysids.

Endocrine Disrupting Chemicals Research Program of the U.S. EnvironmentalProtection Agency: Summary of a Peer-Review Report

At the request of the U.S. Environmental Protection Agency (EPA) Office of Research and Development, a subcommittee of the Board of Scientific Counselors Executive Committee conducted an independent and open peer review of the Endocrine Disrupting Chemicals Research Program (EDC Research Program) of the U.S. EPA. The subcommittee was charged with reviewing the design, relevance, progress, scientific leadership, and resources of the program. The subcommittee found that the long-term goals and science questions in the EDC Program are appropriate and represent an understandable and solid framework for setting research priorities, representing a combination of problem-driven and core research. Long-term goal (LTG) 1, dealing with the underlying science surrounding endocrine disruptors, provides a solid scientific foundation for conducting risk assessments and making risk management decisions. LTG 2, dealing with defining the extent of the impact of endocrine-disrupting chemicals (EDCs), has shown greater progress on ecologic effects of EDCs compared with that on human health effects. LTG 3, which involves support of the Endocrine Disruptor Screening and Testing Program of the U.S. EPA, has two mammalian tests already through a validation program and soon available for use. Despite good progress, we recommend that the U.S. EPA a) strengthen their expertise in wildlife toxicology, b) expedite validation of the Endocrine Disruptors Screening and Testing Advisory Committee tests, c) continue dependable funding for the EDC Research Program, d) take a leadership role in the application of “omics” technologies to address many of the science questions critical for evaluating environmental and human health effects of EDCs, and e) continue to sponsor multidisciplinary intramural research and interagency collaborations.

Perils of paradigm: Complexity, policy design, and the Endocrine Disruptor Screening Program

The Endocrine Disruptor Screening Program (EDSP), mandated by the United States Congress in the Food Quality Protection Act of 1996, attempts to protect public health from adverse endocrine effects of synthetic chemical compounds by establishing a new testing regime. But the complexities and uncertainties of endocrine disruption and its broader regulatory and social context all but ensure the failure of this policy. This article addresses the issues facing EDSP comprehensively and in detail, in order to move beyond the current regulatory paradigm and foster discourse on a positive role for scientists in support of EDSP's end goal: to protect public health.

Tunnel vision: The regulation of endocrine disruptors

This study examines the failure of a small but significant element of U.S. chemical regulatory policy: the Endocrine Disruptor Screening Program (EDSP). A range of conditions are implicated in the failure of this program, but one condition, the scientific testing and regulation paradigm (STRP), seems particularly important and ties the failure of EDSP to the failure of other U.S. chemical regulatory programs. This paradigm is a group of assumptions that have driven pesticide (and other chemical) regulatory policy since World War II. This study investigates the relationship between STRP and the failure of EDSP, the potential efficacy of alternatives to this program, and one alternative that broke from this paradigm. Ultimately, this study suggests that we must revise the role of science in regulation in order to find effective alternatives to modern chemical regulatory policy.

Assessment of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture, in the EDSP male and female pubertal protocols.

DE-71, a commercial mixture, was used to test the sensitivity of the female and male pubertal protocol to detect thyroid active chemicals. These protocols are being evaluated for the U.S. EPA's Endocrine Disruptor Screening Program as part of a Tier I Screening Battery. To examine the ability of these protocols to screen for chemicals that induce the clearance of thyroid hormone, we examined male and female Wistar rats following DE-71 exposure. Rats were gavaged daily with 0, 3, 30, or 60 mg/kg DE in corn oil from postnatal day (PND) 23-53 in the male or PND 22-41 in the female. The temporal effects of DE-71 on liver enzymes and thyroid hormones were measured in another group of males and females following only 5 days of dosing (PND 21 to 26 in females and PND 23 to 28 in males). Serum T4 was significantly decreased at 30 and 60 mg/kg following the 5-day exposures and in the 21-day exposed females. Doses of 3, 30, and 60 mg/kg decreased T4 in 31-day exposed males. Serum T3 was decreased and TSH elevated by 30 and 60 mg/kg in the 31-day exposed males only. Decreased colloid area and increased follicular cell heights (indicative of the hypothyroid state) were observed in thyroids of the 60 mg/kg groups of 20- and 31-day exposed female and males. Increased liver-to-body weight ratios coincided with a significant induction of uridinediphosphate-glucuronosyltransferase (UDGPT; two to four-fold), and ethoxy- and pentoxy-resorufin-O-deethylase (EROD and PROD) at the two highest doses in all exposures. Of the androgen dependent tissues in the 31-day exposed males, seminal vesicle (SV) and ventral prostate (VP) weights were reduced at 60 mg/kg, while testes and epididymal weights were not affected. Preputial separation (PPS) was also significantly delayed by doses of 30 and 60 mg/kg. In the female, the 60 mg/kg dose also caused a significant delay in the age of vaginal opening. Based upon the thyroid hormone response data, this study provides evidence that the 31-day alternative Tier 1 male protocol is a more sensitive test protocol than the 5-day or female pubertal protocol for thyrotoxic agents that act via up-regulation of hepatic metabolism. This apparent greater sensitivity may be due a greater body burden attained following the longer dosing regimen as compared with that of the female protocol, or to gender specific differences in thyroid hormone metabolism. Also, the delay in PPS and reduction in SV and VP weights may indicate a modification or inhibition of endogenous androgenic stimulation directly by DE-71 or a secondary effect that occurs in response to a DE-induced change in thyroid hormones.

Factors considered in using birds for evaluating endocrine-disrupting chemicals.

Documented effects on fish and wildlife populations, coupled with evidence from human poisonings, epidemiology, and experimental toxicology, led to the formation of the Endocrine Disruptor Screening Program within the US Environmental Protection Agency. The main objectives of the program are to validate and implement the screens and tests that have been proposed for evaluating possible endocrine-disrupting activity of chemicals. An avian two-generation test is one of the recommended higher tier tests currently undergoing prevalidation. The advantages and disadvantages of the two species of quail considered as candidates, the northern bobwhite (Colinus virginianus) and the Japanese quail (Coturnix japonica), are described as well as the basis for final selection of the Japanese quail. Among the numerous considerations necessary for ultimately optimizing a two-generation test method using birds, the following key factors are discussed: the number of birds used in the test, when to begin exposure of the P generation, selection and exposure of the F1 generation, and endpoints.

Selecting appropriate animal models and experimental designs for endocrine disruptor research and testing studies.

Evidence that chemicals in the environment may cause developmental and reproductive abnormalities in fish and wildlife by disrupting normal endocrine functions has increased concern about potential adverse human health effects from such chemicals. US laws have now been enacted that require the US Environmental Protection Agency (EPA) to develop and validate a screening program to identify chemicals in food and water with potential endocrine-disrupting activity. EPA subsequently proposed an Endocrine Disruptor Screening Program that uses in vitro and in vivo test systems to identify chemicals that may adversely affect humans and ecologically important animal species. However, the endocrine system can be readily modulated by many experimental factors, including diet and the genetic background of the selected animal strain or stock. It is therefore desirable to minimize or avoid factors that cause or contribute to experimental variation in endocrine disruptor research and testing studies. Standard laboratory animal diets contain high and variable levels of phytoestrogens, which can modulate physiologic and behavioral responses similar to both endogenous estrogen as well as exogenous estrogenic chemicals. Other studies have determined that some commonly used outbred mice and rats are less responsive to estrogenic substances than certain inbred mouse and rat strains for various estrogen-sensitive endpoints. It is therefore critical to select appropriate biological models and diets for endocrine disruptor studies that provide optimal sensitivity and specificity to accomplish the research or testing objectives. An introduction is provided to 11 other papers in this issue that review these and other important laboratory animal experimental design considerations in greater detail, and that review laboratory animal and in vitro models currently being used or evaluated for endocrine disruptor research and testing. Selection of appropriate animal models and experimental design parameters for endocrine disruptor research and testing will minimize confounding experimental variables, increase the likelihood of replicable experimental results, and contribute to more reliable and relevant test systems.

The endocrine disruptor screening program: How EPA plans to select an initial group of chemicals for screening

The endocrine disruptor screening program: How EPA plans to select an initial group of chemicals for screening

Significance of experimental studies for assessing adverse effects of endocrine-disrupting chemicals

The U.S. Environmental Protection Agency (USEPA) is developing an endocrine disruptor screening and testing program to detect chemicals that alter hypothalamic-pituitary-gonadal (HPG) function, estrogen, androgen, and thyroid (EAT) hormone synthesis or metabolism and induce androgen (AR) and estrogen (ER) receptor-mediated effects in mammals and other animals. The utility of this approach is based upon the knowledge that mechanisms of endocrine-disrupting chemical (EDC) action are highly conserved at the cellular and molecular levels among vertebrates. Some EDC mechanisms also are shared with invertebrates. High-priority chemicals would be evaluated in a Tier 1 screening (T1S) battery, and chemicals that are positive in T1S would then be tested in Tier 2 (T2). T1S includes in vitro ER and AR receptor binding and/or gene expression, an assessment of steroidogenesis and mammalian (rat) and nonmammalian (fish) in vivo assays. In vivo, the uterotropic assay detects estrogens and antiestrogens, while steroidogenesis, antithyroid activity, antiestrogenicity, and HPG function are assessed in a pubertal female assay. Antiandrogens are detected in the Hershberger assay (weight of androgen-dependent tissues in castrate-immature-male rats). Fish and amphibian assays are also being developed to identify EDCs. Several alternative mammalian in vivo assays have been proposed. Of these, a short-term pubertal male rat assay appears most promising. T1S is designed to be sensitive to EAT activities, but many of the effects detected at the screening level would not be considered adverse, the dosage levels may be high, and the route of administration used may not be the most relevant. However, issues of adversity, dose response, and route(s) of exposure would be resolved in the testing phase. In addition to using an enhanced multigenerational test for Tier 2, an in utero-lactational screening protocol is also being evaluated by USEPA for use in T2 or T1S. For T2, the numbers of endocrine-sensitive end-points and offspring (F1) examined in multigenerational tests need to be expanded for EDCs in a thoughtful manner, based in part upon the results of T1S. In addition, for some chemicals histological examination of 10 adult F1 per sex in only the control and high-dose groups provides inadequate statistical power to detect low-dose lesions induced during development. In these cases, we propose that all the offspring be examined after puberty for gross and histological reproductive abnormalities. Since EDCs, like the phthalates and AR-antagonists, produce characteristic profiles, or syndromes, of adverse effects, data need to be reported in a manner that clearly identifies the proportion of animals displaying one or more of the abnormalities in a syndrome. Consideration should be given to tailoring T2, based on the results of T1S to assure that all of the effects in such chemically induced developmental syndromes are included in the study.

Endocrine Disruptors: Can Biological Effects and Environmental Risks Be Predicted?

A large number of diverse nonsteroidal chemicals, referred to as xenoestrogens, bind to the estrogen receptor (ER) and evoke biological responses. The activity of most xenoestrogens is weak (from about 1/1000th to 1/1,000,000th that of estradiol). These substances interact with the binding pocket of the ER because they have chemical similarities to estradiol (usually a phenolic A-ring). Reduced activity of xenoestrogens probably results from lack of fit of the remainder of the molecule within the binding pocket. ER binding per se has only limited influence on endocrine disruption. The nature (estrogenic or antiestrogenic) or magnitude of the response is a function of the substance itself, complexities within the various stages of the ER signaling pathway, as well as other factors (such as, plasma binding of xenoestrogens, cross-talk between ER and other signaling pathways, androgen antagonism, and alternate modes of estrogen action). Whereas there is general agreement that high doses of nonsteroidal chemicals can evoke endocrine disruptive effects, there is no consensus that such substances produce low-dose effects or that humans are at risk of endocrine disruption due to exposure to environmentally relevant levels of such chemicals. Furthermore, screening programs to identify hormonally active chemicals (such as the Endocrine Disruptor Screening Program) may be premature in view of the complexity of the mechanisms involved.

Endocrine disruptors: a new scientific role for clinical pharmacologists? Impact on human health, wildlife, and the environment.

It is important for the clinical pharmacologist to understand the potential human health implications of exposure to environmental chemicals that may act as hormonally active agents. It is necessary to have an understanding of how pharmaceutical and personal care products and other chemicals affect the ecosystem of planet Earth and to understand how they may negatively contribute to human disease. Clinical pharmacologists must understand the various definitions of endocrine disruptors and be able to "decipher" these terms for their patients. Understanding the need for the EPA endocrine disruptor screening program and possessing knowledge of the screening assays used to assess endocrine activity potential are two essential components relevant to the topic of endocrine disruptors. Clinical pharmacologists have an opportunity to play an important role in resolving the question of what role endocrine disruptors play in initiating human disease since some scientists argue that the present evidence is not compelling. Clinical pharmacologists can also play an important role in the evaluation of the risk assessment and use of risk management and risk communication tools required to address public health concerns related to actions of endocrine disruptors. It is important that clinical pharmacologists work with veterinary clinical pharmacologists, toxicologists, industrial chemists, regulators, the scientific community, the general public, and environmental groups to understand the impact of endocrine disruptors on human health, wildlife, and the environment with an ultimate goal to minimize and/or alleviate the unwanted, detrimental effects of the endocrine disruptors.